Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for ₹325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market.
Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in the areas of oncology and non-oncology. The company has a strong product portfolio in the non-oncology segment, with a focus on therapeutic areas such as neurology, cardiology, and gastroenterology. The non-oncology business of Khandelwal Laboratories includes a range of products, including tablets, capsules, and injectables.
The acquisition of Khandelwal Laboratories’ non-oncology business will add over 50 products to Aurobindo Pharma’s portfolio, including some well-established brands. The products will be marketed and distributed by Aurobindo Pharma’s existing sales team, which has a strong presence in the domestic market. The acquisition is expected to be completed in the next few months, subject to regulatory approvals.
Aurobindo Pharma has stated that the acquisition is in line with its strategy to expand its product portfolio and increase its presence in the domestic market. The company has been looking to strengthen its position in the Indian market, where it faces intense competition from other pharmaceutical companies. The acquisition of Khandelwal Laboratories’ non-oncology business is expected to help Aurobindo Pharma achieve this objective.
The acquisition is also expected to be beneficial for Khandelwal Laboratories, as it will allow the company to focus on its oncology business. Khandelwal Laboratories has a strong presence in the oncology segment, and the company is expected to use the proceeds from the sale to invest in its oncology business.
The deal is valued at ₹325 crore, which is a significant amount for a pharmaceutical company of Khandelwal Laboratories’ size. The acquisition price includes the cost of acquiring the non-oncology business, including the products, manufacturing facilities, and marketing rights. Aurobindo Pharma has stated that the acquisition will be funded through a combination of internal accruals and debt.
Overall, the acquisition of Khandelwal Laboratories’ non-oncology business by Aurobindo Pharma is a significant development in the Indian pharmaceutical industry. The deal is expected to strengthen Aurobindo Pharma’s position in the domestic market and provide the company with a strong portfolio of products in the non-oncology segment.